Biogen’s stock fell more than 6% premarket on Friday after European regulators gave a thumbs down to the company’s Alzheimer’s disease treatment, which it markets jointly with Eisai Co. Ltd.
More Stories
Get ready for Netflix price increases soon, analysts say
Netflix hasn’t raised prices on its standard plan in years, and analysts think the company’s strong upcoming content slate could...
Homeowners haven’t drained cash out of their houses this fast since 2008
Homeowners across the U.S. may be locked in, but they can still cash out.
Buy Nike’s stock now, as new management can excite investors again, analyst says
It’s time to start buying Nike Inc.’s stock, as a new management team of company veterans should reignite investor excitement...
Amazon’s Prime Big Deal Days was its biggest-ever October shopping event
Amazon.com Inc. said Thursday its Prime Big Deal Days was its biggest October shopping event ever, as Prime members took...
Where Nvidia ranks among fastest-growing AI companies. No, it’s not No. 1.
Others ranking high on a broad list of AI stocks include AMD and Micron.
Tilray’s stock gains after earnings and upbeat outlook on cannabis legalization
Tilray’s stock gained Thursday, after the cannabis and beverage company reported a smaller loss than expected for its fiscal first...